Year None202420232022202120202019 Feb 16, 2024 Arcutis to Report Fourth Quarter and Full Year 2023 Financial Results Feb 06, 2024 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jan 31, 2024 Arcutis to Present at the Guggenheim Healthcare Talks – 6th Annual Biotechnology Conference Jan 29, 2024 Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% Results for Jan 22, 2024 ZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment of Seborrheic Dermatitis Launches in the Jan 14, 2024 ZORYVE® (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Jan 14, 2024 Majority of Individuals with Atopic Dermatitis Improved with Arcutis’ Roflumilast Cream 0.15% Accord First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Current page 4 Displaying 28 - 34 of 34